Truist Financial Corp Novo Cure LTD Transaction History

Truist Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	BUY	$40.29 - $82.51 $141,095 - $288,950	3,502 Added 38.33%	12,638 $524,000
Q1 2023 May 05, 2023	SELL	$56.44 - $118.81 $137,882 - $290,252	-2,443 Reduced 21.1%	9,136 $549,000
Q4 2022 Feb 17, 2023	BUY	$63.98 - $85.37 $41,395 - $55,234	647 Added 5.92%	11,579 $849,000
Q3 2022 Oct 26, 2022	BUY	$67.99 - $89.57 $104,024 - $137,042	1,530 Added 16.27%	10,932 $831,000
Q2 2022 Jul 22, 2022	BUY	$56.6 - $89.9 $532,153 - $845,239	9,402 New	9,402 $653,000
Q1 2021 May 17, 2021	SELL	$124.11 - $190.17 $247,351 - $379,008	-1,993 Closed	0 $0
Q4 2020 Nov 19, 2021	SELL	$112.16 - $174.14 $410,056 - $636,655	-3,656 Reduced 64.72%	1,993 $345,000
Q4 2020 Feb 18, 2021	BUY	$112.16 - $174.14 $423,628 - $657,726	3,777 Added 201.76%	5,649 $978,000
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $108,669 - $208,372	1,872 New	1,872 $208,000
Q2 2020 Aug 14, 2020	SELL	$57.2 - $74.41 $310,710 - $404,195	-5,432 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$57.05 - $95.75 $201,957 - $338,955	-3,540 Reduced 39.46%	5,432 $365,000
Q4 2019 Feb 14, 2020	BUY	$68.3 - $93.8 $612,787 - $841,573	8,972 New	8,972 $756,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.04B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.